Targeted Therapies for Pancreatic Cancer

被引：63

作者：

Amanam, Idoroenyi ^{[1
]}

Chung, Vincent ^{[1
]}

机构：

[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA

来源：

CANCERS | 2018年 / 10卷 / 02期

关键词：

targeted therapy; personalized medicine; pancreas; PHASE-III TRIAL; GEMCITABINE PLUS PLACEBO; TUMOR-SUPPRESSOR GENE; HUMAN HOMOLOG; INHIBITION; SURVIVAL; ADENOCARCINOMA; MAINTENANCE; KRAS; MULTICENTER;

D O I：

10.3390/cancers10020036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has been incremental with median overall survival remaining less than one year. There is an urgent need for improved therapies with better efficacy and less toxicity. Small molecule inhibitors, monoclonal antibodies and immune modulatory therapies have been used. Here we review the progress that we have made with these targeted therapies.

引用

页数：14

共 71 条

[61] T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer [J].

Tran, Eric ;

Robbins, Paul F. ;

Lu, Yong-Chen ;

Prickett, Todd D. ;

Gartner, Jared J. ;

Jia, Li ;

Pasetto, Anna ;

Zheng, Zhili ;

Ray, Satyajit ;

Groh, Eric M. ;

Kriley, Isaac R. ;

Rosenberg, Steven A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (23) :2255-2262

[62] The MEK/ERK Pathway Promotes NOTCH Signalling in Pancreatic Cancer Cells [J].

Tremblay, Isabelle ;

Pare, Emanuel ;

Arsenault, Dominique ;

Douziech, Melanie ;

Boucher, Marie-Josee .

PLOS ONE, 2013, 8 (12)

[63] Hallmarks of 'BRCAness' in sporadic cancers [J].

Turner, N ;

Tutt, A ;

Ashworth, A .

NATURE REVIEWS CANCER, 2004, 4 (10) :814-819

[64] p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway [J].

Tyagi, Nikhil ;

Bhardwaj, Arun ;

Singh, Ajay P. ;

McClellan, Steven ;

Carter, James E. ;

Singh, Seema .

ONCOTARGET, 2014, 5 (18) :8778-8789

[65] Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer [J].

Van Cutsem, E ;

de Velde, HV ;

Karasek, P ;

Oettle, H ;

Vervenne, WL ;

Szawlowski, A ;

Schoffski, P ;

Post, S ;

Verslype, C ;

Neumann, H ;

Safran, H ;

Humblet, Y ;

Ruixo, JP ;

Ma, Y ;

Von Hoff, D .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1430-1438

[66] Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine [J].

Von Hoff, Daniel D. ;

Ervin, Thomas ;

Arena, Francis P. ;

Chiorean, E. Gabriela ;

Infante, Jeffrey ;

Moore, Malcolm ;

Seay, Thomas ;

Tjulandin, Sergei A. ;

Ma, Wen Wee ;

Saleh, Mansoor N. ;

Harris, Marion ;

Reni, Michele ;

Dowden, Scot ;

Laheru, Daniel ;

Bahary, Nathan ;

Ramanathan, Ramesh K. ;

Tabernero, Josep ;

Hidalgo, Manuel ;

Goldstein, David ;

Van Cutsem, Eric ;

Wei, Xinyu ;

Iglesias, Jose ;

Renschler, Markus F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (18) :1691-1703

[67]

Weekes Colin D, 2011, Cancers (Basel), V3, P3676, DOI 10.3390/cancers3033676

[68] THE RETINOBLASTOMA PROTEIN AND CELL-CYCLE CONTROL [J].

WEINBERG, RA .

CELL, 1995, 81 (03) :323-330

[69] Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets [J].

Witkiewicz, Agnieszka K. ;

McMillan, Elizabeth A. ;

Balaji, Uthra ;

Baek, GuemHee ;

Lin, Wan-Chi ;

Mansour, John ;

Mollaee, Mehri ;

Wagner, Kay-Uwe ;

Koduru, Prasad ;

Yopp, Adam ;

Choti, Michael A. ;

Yeo, Charles J. ;

McCue, Peter ;

White, Michael A. ;

Knudsen, Erik S. .

NATURE COMMUNICATIONS, 2015, 6

[70] EPIDERMAL GROWTH-FACTOR INDUCES RAPID, REVERSIBLE AGGREGATION OF THE PURIFIED EPIDERMAL GROWTH-FACTOR RECEPTOR [J].

YARDEN, Y ;

SCHLESSINGER, J .

BIOCHEMISTRY, 1987, 26 (05) :1443-1451

← 1 2 3 4 5 6 7 8 →